Revive Therapeutics Ltd
WKN: A2AP4F / ISIN: CA7615161030Revive Therapeutics Ltd. (RVV.CN)
| eröffnet am: | 30.03.20 10:25 von: | Chalifmann3 |
| neuester Beitrag: | 25.04.21 00:01 von: | Kristinujjua |
| Anzahl Beiträge: | 179 | |
| Leser gesamt: | 62692 | |
| davon Heute: | 6 | |
bewertet mit 1 Stern |
||
|
|
||
16.02.21 05:59
#176
axolot
RVVTF für mich eine der spannendsten Aktien 2021
..... könnte heute richtig schön nach oben laufen
https://www.tradingview.com/symbols/OTC-RVVTF/
https://www.tradingview.com/symbols/OTC-RVVTF/
16.02.21 06:14
#177
axolot
RVVTF jetzt auf Rebbit !
Great post on Reddit. Peeps are starting to talk about it and the shorters would be toast.
https://www.reddit.com/r/RVVTF/comments/lhra14/...bucillamines_phase/
https://www.reddit.com/r/RVVTF/comments/lhra14/...bucillamines_phase/
19.03.21 12:53
#179
axolot
NEWS gerade raus
RVVTF...387...Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of International Patent Application
TORONTO, March 19, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the treatment of mild traumatic brain injury (“TBI”) in a rodent model of TBI. The study was conducted at the National Health Research Institutes (“NHRI”), which was part of the psilocybin program acquired from PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM, OTCQB: PHRRF)...
TORONTO, March 19, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce positive results of a pre-clinical study evaluating the efficacy of psilocybin in the treatment of mild traumatic brain injury (“TBI”) in a rodent model of TBI. The study was conducted at the National Health Research Institutes (“NHRI”), which was part of the psilocybin program acquired from PharmaTher Inc., a subsidiary of Newscope Capital Corporation (CSE: PHRM, OTCQB: PHRRF)...

